Table 2.

Significant HPV vaccine outcomes among experimental interventions

Study Design	Vaccine Outcomes	Significance	Multi Component	Multi Level
Experimental (n = 47)	11 (23.4%) measured Vaccine Initiation (VI) [26, 31, 44, 48, 52, 55, 58, 74, 79, 82, 100]	3 (27.0%) found a significant increase in VI [44, 74, 79]
	3 (6.4%) measured Vaccine Completion (VC) [75, 78, 93]	None found a significant increase in VC
	11 (23.4%) measured Vaccine Initiation and Vaccine Completion (both) [30, 35, 40, 46, 50, 51, 59, 64, 76, 85, 94]	3 (27.0%) found a significant increase in VI [46, 59, 94] 1 (9.1%) found a significant increase in VC [76] 2 (18.2%) found significant increases for both [30, 64]
		Total Significance: 9 total articles had a significant increase in either VI, VC, or both [30, 44, 46, 59, 64, 74, 76, 79, 94]	6 (66.7%) were multi component [30, 46, 59, 74, 76, 79]	4 (44.4%) were multilevel [30, 59, 79, 94]